Final Program Introduction of CVRF
| Date | Time | Place | Session / Title | Role |
| April 30 | 7:00 AM - 8:00 AM | Room 105, Level 1 | Antithrombotic Therapy | Moderator |
| April 30 | 7:30 AM - 7:42 AM | Room 105, Level 1 | Antithrombotic Therapy Aspirin Plus P2Y12 Inhibitor Still Remains as a Key Player. |
Lecturer |
| April 30 | 10:30 AM - 11:00 AM | Interview Lounge, Level 3 | Non-vitamin K antagonist Oral Anticoagulants(NOACs) in Atherosclerotic Cardiovascular Disease | Interviewee |
| April 30 | 12:46 PM - 12:57 PM | Room 105, Level 1 | The New Standard for High Bleeding Risk Patients:1 Month DAPT with BioFreedom® "Who Are HBR Patients?" - Identification of HBR Patients in Clinical Practice |
Lecturer |
| April 30 | 2:00 PM - 3:06 PM | Room 104, Level 1 | Spotlights of Major Clinical Studies with Expert Commentary | Discussant |
| April 30 | 2:33 PM - 2:40 PM | Room 104, Level 1 | Spotlights of Major Clinical Studies with Expert Commentary Why DAPT Trial Not Followed?: Moving Forward Less Duration with Smart DES, De-Escalating Strategy, and P2Y12 Inhibitor Monotherapy |
Lecturer |
| April 30 | 2:51 PM - 2:55 PM | Room 104, Level 1 | Spotlights of Major Clinical Studies with Expert Commentary Discussion: Expanding Role of NOAC in PCI/AF, ACS, and Stable ASCVD: Recent Trials and Next Expectations |
Discussant |
